News | May 13, 2021
Eris Lifesciences reports Q4FY21 consolidated net profit of Rs. 68.24 Cr
Eris Lifesciences has reported total income of Rs.1220.57 crores during the 12 months period ended March 31, 2021
Eris Lifesciences has reported total income of Rs.1220.57 crores during the 12 months period ended March 31, 2021
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
The additional allocation of Tocilizumab will ensure sufficient availability for COVID-19 patients and augment the government’s efforts to fight the pandemic
Alembic has reported total income of Rs.83.79 crores during the FY ended March 31, 2021
Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil maintained their leadership positions in-their respective categories as on March 2021.
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
The company reported total income of Rs.390.05 crores during the 12 months period ended March 31, 2021
The companyreported total income of Rs.2915.67 crores during the 12 months period ended March 31, 2021
Subscribe To Our Newsletter & Stay Updated
